Unifor and Ford Motor Company have begun collective bargaining talks. Canada's largest private sector union anticipates this round of negotiations will be the most consequential in its history for the automotive industry.

Pfizer announced that its experimental lung cancer drug, sigvotatug vedotin, failed to improve survival in patients with an advanced form of non-small cell lung cancer that could not be treated with surgery. This setback follows Pfizer's $43 billion acquisition of Seagen Inc. in late 2023, with expectations that the drug would be a groundbreaking antibody-drug conjugate. Despite the disappointing trial results, Pfizer remains committed to the drug's development, especially in combination with Merck's Keytruda for earlier-stage treatment.

This article announces the filing of Form S-3/A by RenX Enterprises Corp for June 22. It provides no further details about the filing but is framed within a standard stock market news update from Investing.com. The information is concise, indicating a regulatory filing without offering analysis or commentary.

The European Commission has approved the acquisition of ES Group Holdings III Limited (UK) by Blackstone Inc. (US) under the EU Merger Regulation. The transaction, primarily involving mineral-based products and solid surface technologies for bathrooms, was examined under a simplified review procedure. The Commission concluded that the acquisition would not raise competition concerns due to the companies' limited market positions post-transaction.

The article highlights the Dayton 3-Phase General Purpose Motor from W.W. Grainger Inc, describing it as a robust and versatile workhorse essential for demanding industrial environments. It emphasizes the motor's reliability, ease of integration, and its importance to W.W. Grainger's business, despite not being a flashy product. The piece explains how this general-purpose motor serves various industries and contributes to the company's strong market position.

US stock index futures declined on Monday evening, primarily driven by continued skittishness in the technology sector following significant losses in Alphabet and SpaceX. Investors are also monitoring ongoing U.S.-Iran peace negotiations, which have shown some progress, and upcoming economic data, including purchasing managers index data, revised GDP figures, and the PCE price index, for clues on interest rate policy.

Penumbra Inc. shareholders met to elect three Class II directors to serve until the 2027 annual meeting, ratify PricewaterhouseCoopers LLP as the independent public accounting firm, and approve executive compensation. The medical device company also recently received CE Mark approval for its THUNDERBOLT device in Europe and FDA clearance in the U.S., and shareholders approved a merger with Boston Scientific Corporation. Additionally, results from the STORM-PE trial indicated improved patient outcomes using Penumbra’s technology for pulmonary embolism.

AMETEK Inc. has released the PAROS 20-IMV-1 Shipboard Barometer, a compact, rugged pressure sensor designed for commercial vessels and research ships. This barometer provides stable and low-noise atmospheric pressure measurements for navigation, weather logging, and safety, even in harsh marine environments. It integrates easily with existing bridge systems, contributing to AMETEK's portfolio of instrumentation for long-term growth and recurring revenue from service contracts.

Levi & Korsinsky, LLP has filed a securities class action lawsuit against Zoetis Inc. (NYSE: ZTS) on behalf of investors who purchased securities between January 14, 2025, and May 6, 2026. The lawsuit alleges that Zoetis made false statements and/or concealed issues regarding weakening prescription growth for Librela due to FDA safety warnings, market share loss for Simparica Trio, and diminishing market share for its dermatology products, Apoquel and Cytopoint. Shareholders who suffered losses are encouraged to contact Levi & Korsinsky by the July 27, 2026 deadline to explore potential recovery.

Ambetter Health Virtual Access by Centene Corp. offers a digital-first health insurance plan with $0 virtual primary care visits, aiming to provide convenient and cost-effective healthcare. This subscription-style product integrates telehealth with a curated network, allowing members to manage routine consultations, urgent care, and prescriptions through an app. The service targets digitally-inclined individuals in selected US states, with pricing varying by metal tier and subsidies, and is a key part of Centene's strategy to meet members "where they are" while managing costs.